Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
Overview | Financials
Company Name | Supernus Pharmaceuticals, Inc. |
Symbol | SUPN |
Currency | USD |
Price | 36.43 |
Market Cap | 2,011,639,099 |
Dividend Yield | 0% |
52-week-range | 25.53 - 39.37 |
Industry | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. Jack A. Khattar |
Website | https://www.supernus.com |
An error occurred while fetching data.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD